Polymorphism of the p38β gene in patients with colorectal cancer

Dimberg,Jan; Olsen,Renate  Slind; Skarstedt,Marita; Löfgren,Sture; Zar,Niklas; Matussek,Andreas

doi:10.3892/ol.2014.2315

Polymorphism of the p38β gene in patients with colorectal cancer

Authors:
- Jan Dimberg
- Renate Slind Olsen
- Marita Skarstedt
- Sture Löfgren
- Niklas Zar
- Andreas Matussek
View Affiliations

Affiliations: Department of Natural Science and Biomedicine, University College of Health Sciences, Jönköping, SE‑551 11, Sweden, Department of Laboratory Services, Ryhov County Hospital, Jönköping, SE‑551 85, Sweden, Department of Clinical Microbiology, Ryhov County Hospital, Jönköping, SE‑551 85, Sweden, Departments of Surgery, Ryhov County Hospital, Jönköping, SE‑551 85, Sweden
Published online on: July 4, 2014 https://doi.org/10.3892/ol.2014.2315
Pages: 1093-1095

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The p38 mitogen‑activated protein kinase (MAPK) signaling pathways have been proposed to participate in the pathological process of cancer by affecting inflammation, proliferation, metastasis and cell survival. A single nucleotide polymorphism (SNP; rs2235356, ‑1628A→G) in the promoter region of the p38β gene has been proposed as a genetic modifier for colorectal cancer (CRC) in a Chinese population. The present study evaluated the susceptibility of patients possessing this SNP to CRC, in addition to determining its association with clinical parameters in Swedish patients with CRC. Using the LightSNiP genotyping assay, this SNP was screened in 389 patients with CRC and 517 control subjects. No significant difference in the genotype distribution or in the allelic frequencies was identified between the two groups nor was any association identified with the clinical parameters. These findings indicate that the ‑1628A→G polymorphism of the p38β gene is not significantly associated with a susceptibility to CRC in a Swedish population.

View Figures

View References

1	Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M and Warusavitarne J: Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 27:1423–1431. 2012.
2	Markowitz SD and Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 361:2449–2460. 2009.
3	Kondo Y and Issa JP: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004.
4	Naghibalhossaini F, Zamani M, Mokarram P, Khalili I, Rasti M and Mostafavi-Pour Z: Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Mol Biol Rep. 39:6171–6178. 2012.
5	Mammano E, Belluco C, Bonafé M, Olivieri F, Mugianesi E, Barbi C, Mishto M, Cosci M, Franceschi C, Lise M and Nitti D: Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol. 35:415–419. 2009.
6	Theodoropoulos G, Papaconstantinou I, Felekouras E, Niketeas N, Karakitsos P, Panoussopoulos D, Lazaris ACh, Patsouris E, Bramis J and Gazouli M: Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol. 12:5037–5043. 2006.
7	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002.
8	Van Nguyen S, Skarstedt M, Löfgren S, Zar N, Andersson RE, Lindh M, Matussek A and Dimberg J: Gene polymorphism of matrix metalloproteinase-12 and -13 and association with colorectal cancer in Swedish patients. Anticancer Res. 33:3247–3250. 2013.
9	Fang JY and Richardson BC: The MAPK signaling pathways and colorectal cancer. Lancet Oncol. 6:322–327. 2005.
10	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signaling pathways in cancer. Oncogene. 26:3279–3290. 2007.
11	Zarubin T and Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res. 15:11–18. 2005.
12	Pailas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, et al: Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res. 71:1041–1049. 2011.
13	Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG and Brown PH: Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 69:8853–8861. 2009.
14	Huang Q, Chen D, Song S, Fu X, Wei Y, Lu J, Wang L and Wang J: A genetic variation of the p38β promoter region is correlated with an increased risk of sporadic colorectal cancer. Oncol Lett. 6:3–8. 2013.
15	Wu JS: Rectal cancer staging. Clin Colon Rectal Surg. 20:148–157. 2007.
16	del Barco Barrantes I and Nebreda AR: Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans. 40:79–84. 2012.
17	Jormsjö S, Ye S, Moritz J, Walter DH, Dimmeler S, Zeiher AM, Henney A, Hamsten A and Eriksson P: Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res. 86:998–1003. 2000.
18	Benbow U and Brinckerhoff CE: The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol. 15:519–526. 1997.
19	Simon C, Simon M, Vucelic G, Hicks MJ, Plinkert PK, Koitschev A and Zenner HP: The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp Cell Res. 271:344–345. 2001.
20	Ashida R, Tominaga K, Sasaki E, Watanabe T, Fujiwana Y, Oshitani N, Higuchi K, Mitsuyama S, Iwao H and Arakawa T: AP-1 and colorectal cancer. Inflammopharmacology. 13:113–125. 2005.